Skip to content

A randomized controlled clinical trial of platelet function index to guide platelet transfusion in pregnancy complicated with thrombocytopenia

A randomized controlled clinical trial of platelet function index to guide platelet transfusion in pregnancy complicated with thrombocytopenia

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100049486
Enrollment
Unknown
Registered
2021-08-02
Start date
2021-08-02
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy with thrombocytopenia

Interventions

Experimental group:Non-imported platelets

Sponsors

Department of Blood Transfusion, Shengjing Hospital, China Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Pregnant women; 2. Indicated cesarean section is planned; 3. Agree to prenatal platelet count and TEG test; 4. Platelet count before delivery =55mm; 6. Voluntarily participate and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant women who intend to give birth naturally; 2. Complicated with one of the following complications: placenta previa; placenta accreta; placental abruption; twins; intrauterine stillbirth; uterine rupture; amniotic fluid embolism; pregnancy complicated with acute fatty liver and other high-risk groups of postpartum hemorrhage 3. Patients with moderate to severe anemia before delivery, hemoglobin <=80g/L; 4. Patients with combined cardiopulmonary insufficiency; 5.MA<55mm, indicating that the platelet aggregation function is reduced; 6. Other obstetricians believe that the trial population cannot be satisfied; 7. Patients who do not agree to participate in this study or do not sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
Platelet count;Thromboelastogram;Platelet count;Thromboelastogram;Thromboelastogram;Platelet count;Hemoglobin;Hemoglobin;

Secondary

MeasureTime frame
White blood cell count;White blood cell count;White blood cell count;Red blood cell count;Red blood cell count;Red blood cell count;Hemoglobin;Mean platelet volume;Mean platelet volume;Mean platelet volume;plateletcrit;plateletcrit;plateletcrit;Platelet distribution width;Platelet distribution width;Platelet distribution width;Reticulocyte count;Reticulocyte count;Reticulocyte count;Thrombin time;Thrombin time;Thrombin time;Prothrombin time;Prothrombin time;Prothrombin time;Activated partial thromboplastin time;Activated partial thromboplastin time;Activated partial thromboplastin time;Fibrinogen;Fibrinogen;Fibrinogen;D dimer;

Countries

China

Contacts

Public ContactWang Qiushi

Shengjing Hospital Affiliated to China Medical University

wangqs18@vip.126.com+86 18940251212

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026